NASDAQ:ACOR Acorda Therapeutics (ACOR) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.66▼$15.6052-Week Range N/AVolume416,900 shsAverage Volume119,299 shsMarket Capitalization$820,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsStock AnalysisEarningsHeadlinesInsider TradesOwnershipShort InterestTrends Get Acorda Therapeutics alerts: Email Address Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Acorda Therapeutics Stock (NASDAQ:ACOR)Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.Read More Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. ACOR Stock News HeadlinesMay 16, 2024 | msn.comEssential cancer treatment company files Chapter 11 bankruptcyApril 15, 2024 | businesswire.comAcorda Therapeutics Announces Delisting from NasdaqJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.April 14, 2024 | wsj.comAcorda Therapeutics Inc.April 8, 2024 | msn.comPearl River-based Acorda Therapeutics to close; 97 jobs impactedApril 6, 2024 | finance.yahoo.comRiskiest Junk Bonds Shunned in Europe on Rising Risk of DefaultApril 3, 2024 | businesswire.comAcorda Therapeutics Announces Nasdaq Delisting NotificationApril 3, 2024 | baystreet.caAcorda Therapeutics Files for Chapter 11 BankruptcyJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.April 2, 2024 | msn.comCrude Oil Surges Over 1%; US Factory Orders Increase In FebruaryApril 2, 2024 | benzinga.comWhy Acorda Therapeutics Stock Is Down Nearly 90%April 2, 2024 | investorplace.comWhy Is Acorda Therapeutics (ACOR) Stock Down 72% Today?April 2, 2024 | morningstar.comNorth American Morning Briefing: Stocks Seen Weaker as Doubts Over Fed Cuts MountApril 2, 2024 | finanznachrichten.deMerz Therapeutics: Merz Enters Asset Purchase Agreement With a US-Based Biotech CompanyApril 1, 2024 | msn.comAcorda retires from PNP after 3 months of extended serviceApril 1, 2024 | msn.comRetired PNP chief Acorda: I did my bestApril 1, 2024 | marketwatch.comStocks to Watch: PVH, Canoo, Acorda TherapeuticsApril 1, 2024 | msn.comAcorda Therapeutics shares sink nearly 40% after bankruptcy filingSee More Headlines Receive ACOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acorda Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:ACOR CUSIP00484M10 CIK1008848 Webwww.acorda.com Phone(914) 347-4300Fax914-347-4560Employees111Year Founded1995Profitability EPS (Most Recent Fiscal Year)($203.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-252,850,000.00 Net Margins-214.95% Pretax Margin-251.65% Return on Equity-2,206.93% Return on Assets-83.28% Debt Debt-to-Equity Ratio3.07 Current Ratio0.33 Quick Ratio0.26 Sales & Book Value Annual Sales$117.63 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow0.02 Book Value($127.17) per share Price / BookN/AMiscellaneous Outstanding Shares1,240,000Free Float1,210,000Market Cap$820,000.00 OptionableNo Data Beta1.40 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Ron Cohen M.D. (Age 68)Founder, CEO, President & Director Comp: $984.15kMr. Michael A. Gesser M.B.A. (Age 61)Chief Financial Officer Comp: $459.15kMr. Kerry M. Clem (Age 54)Chief Commercial Officer Comp: $592.23kMr. Robert Morales (Age 56)Interim Principal Accounting Officer, Principal Financial Officer, VP of Finance & Controller Ms. Felicia VonellaVice President of Investor RelationsMr. Neil S. Belloff Esq. (Age 64)General Counsel & Corporate Secretary Ms. Tierney SaccavinoExecutive Vice President of Corporate CommunicationsMs. Denise J. DucaExecutive Vice President of Human ResourcesMr. Andrew Mayer J.D.Senior Vice PresidentSofia AliSenior VP of Operations & Strategic PlanningMore ExecutivesKey CompetitorsaTyr PharmaNASDAQ:LIFEOcugenNASDAQ:OCGNAmgenNASDAQ:AMGNVertex PharmaceuticalsNASDAQ:VRTXRegeneron PharmaceuticalsNASDAQ:REGNView All Competitors ACOR Stock Analysis - Frequently Asked Questions How were Acorda Therapeutics' earnings last quarter? Acorda Therapeutics, Inc. (NASDAQ:ACOR) released its quarterly earnings data on Tuesday, November, 9th. The biopharmaceutical company reported ($28.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($31.20) by $2.60. The biopharmaceutical company earned $31.46 million during the quarter, compared to the consensus estimate of $30.57 million. Acorda Therapeutics had a negative net margin of 214.95% and a negative trailing twelve-month return on equity of 2,206.93%. When did Acorda Therapeutics' stock split? Shares of Acorda Therapeutics reverse split on the morning of Monday, June 5th 2023. The 1-20 reverse split was announced on Monday, June 5th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What is Ron Cohen's approval rating as Acorda Therapeutics' CEO? 39 employees have rated Acorda Therapeutics Chief Executive Officer Ron Cohen on Glassdoor.com. Ron Cohen has an approval rating of 55% among the company's employees. This puts Ron Cohen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Acorda Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Acorda Therapeutics investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), InterDigital (IDCC), Nektar Therapeutics (NKTR), Rigel Pharmaceuticals (RIGL) and Novan (NOVN). This page (NASDAQ:ACOR) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acorda Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acorda Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.